A review in Nature Reviews Endocrinology sets out what is known about how closely stem cell-derived pancreatic beta cells and stem cell-derived islets resemble primary human ones. The received explanation for the differences has been incomplete maturation in vitro. The authors argue that this does not cover the observations: cells matured further in vivo still differ considerably from mature primary islet cells.
The reason this is worth a clinician's attention rather than only a bench scientist's is that stem cell-derived islet products are already in clinical trials for type 1 diabetes. How well the transplanted cells behave like real islets - glucose sensing, secretory dynamics, composition of the graft - is the thing that determines whether a graft functions physiologically or merely secretes insulin. The review's practical demand is methodological: comparable tissue quality, harmonised assays, shared datasets, so that trial results can be interpreted against a known baseline.
Nothing here changes management. It is a reason to be careful with the language used when patients ask about a cure - the trials are real, and the cells in them are not yet equivalent to the ones they replace.
- Expect patients with type 1 diabetes to raise stem cell islet trials; know that they exist and are early phase
- Distinguish, when asked, between insulin secretion from a graft and physiological glucose regulation
- Immunosuppression remains part of the current transplant proposition - say so when the subject comes up
- Do not let trial enthusiasm displace the immediate work of technology, targets and follow-up
- Point interested patients to registered trials rather than to clinics advertising stem cell therapy
Why it matters
It undercuts the assumption that time in the body finishes the job of maturing these cells - which is the assumption the field's timelines were built on.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free